Advertisement
UK markets open in 1 hour 29 minutes
  • NIKKEI 225

    38,066.08
    +104.28 (+0.27%)
     
  • HANG SENG

    16,381.83
    +129.99 (+0.80%)
     
  • CRUDE OIL

    82.82
    +0.13 (+0.16%)
     
  • GOLD FUTURES

    2,389.70
    +1.30 (+0.05%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • Bitcoin GBP

    49,491.96
    -2,002.15 (-3.89%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     
  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     

How Has CymaBay Therapeutics Performed Financially?

How Has CymaBay Therapeutics Performed Financially?

CymaBay Therapeutics’ (CBAY) MBX-2982 is under evaluation as a novel therapeutic agent. The company has yet to disclose its target indication. The drug was synthesized as a GPR119 agonist and is shown to increase glucose-dependent insulin secretion in animal models and in vitro. Non-clinical studies have shown MBX-2982 to have desirable effects on blood glucose levels.